Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable HF as defined by:~* No hospitalization for \>60 days~* Stable HF medications for \>=2 weeks, and stable diuretics for 4 weeks~* Opinion of HF cardiologist that the patient is at their optimal volume status~* Chronic daily oral loop diuretic dose \>=20mg furosemide equivalents~* Diagnosis of type II diabetes~* Patient monitors blood glucose regularly at home~* eGFR \>=45 mL/min/1.73 m2~* \>=18 years old~Exclusion Criteria:~* Active titration of chronic HF medications expected during the study period~* Use of a non-loop diuretic, aside from an aldosterone antagonist (\<=25mg spironolactone or \<=50mg eplerenone)~* Critical stenotic valvular disease, complex congenital heart disease, or prior heart transplant~* History of diabetic ketoacidosis, brittle diabetes, and/or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months~* History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections~* Anemia (defined as hemoglobin \<8g/dL)~* Pregnancy or breastfeeding~* History of serious hypersensitivity~* Participation in another trial with an investigational drug within the 30 days prior to informed consent~* Use of another SGLT-2 inhibitor~* Appears unlikely, or unable to participate in the required study procedures, as assessed by the study PI or research RN (ex: clinically-significant psychiatric, addictive, or neurological disease)~* Inability to give written informed consent or follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, then empagliflozin (Type: EXPERIMENTAL): Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy.
- Empagliflozin, then Placebo (Type: EXPERIMENTAL): Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).